| ID | 1228 |
| Name of the vaccine | J5-OMP vaccine |
| Microbe | Bacteria |
| Disease name | Bacterial Sepsis |
| Name of bacteria | E.coli, group B Streptococcus, Neisseria meningitidis, Salmonella, Haemophilus influenzae type b, and Listeria monocytogenes. |
| Type of vaccine | Subunit |
| Nucleic acid content | DNA |
| Age | 18 to 50 years |
| Description of the vaccine | Detoxified J5 core glycolipid/ group B Meningococcal outer membrane protein vaccine. |
| Name of the manufacturer | National Institute of Allergy and Infectious Diseases (NIAID) |
| Name of the manufacturing country | United States |
| Year of manufacture | 2013 |
| Clinical Phase status | Clinical - Terminated |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three-dose regimen on days 0, 29 and 59. |
| Mechanism of action | Anti-J5 dLPS antibody. |
| Route of administration | Intramuscular |
| Indications | Treatment of gram negative sepsis. |
| Export | NA |
| Approval | NA |
| Adjuvant | With or without synthetic CPG oligodeoxynucleotide 7909 (CPG 7909). |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 20593272 |
| Clinical trial number | NCT01164514 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|